Publisher
Springer Science and Business Media LLC
Reference39 articles.
1. U.S. Cancer Statistics Working Group (2022) U.S. Cancer statistics data visualizations tool, based on 2021 submission data (1999–2019). U.S. Department of Health and Human Services, Centers for Disease Control and Prevention and National Cancer Institute. https://www.cdc.gov/cancer/breast/statistics/index.htm. Accessed 13 Sept 2022
2. Early Breast Cancer Trialists’ Collaborative Group (2011) Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials. Lancet (London, England) 378(9793):771–784
3. Early Breast Cancer Trialists’ Collaborative Group (2015) Aromatase inhibitors versus tamoxifen in early breast cancer: patient-level meta-analysis of the randomised trials. Lancet (London, England) 386(10001):1341–1352
4. Burstein HJ, Lacchetti C, Anderson H, Buchholz TA, Davidson NE, Gelmon KA, Giordano SH, Hudis CA, Solky AJ, Stearns V, Winer EP, Griggs JJ (2019) Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J Clin Oncol 37(5):423–438
5. National Comprehensive Cancer Network (2021) NCCN clinical practice guidelines in oncology. Breast Cancer. Version 5.2021. https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf. Accessed 1 Jul 2021
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献